Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 14 | 2021 | 1177 | 3.950 |
Why?
|
| Transplantation, Heterologous | 7 | 2022 | 370 | 2.460 |
Why?
|
| Graft Survival | 14 | 2022 | 898 | 1.910 |
Why?
|
| Thrombocytopenia | 4 | 2022 | 187 | 1.890 |
Why?
|
| Living Donors | 7 | 2021 | 339 | 1.880 |
Why?
|
| Kidney Transplantation | 12 | 2018 | 849 | 1.840 |
Why?
|
| Liver | 6 | 2022 | 1205 | 1.590 |
Why?
|
| Hepatectomy | 3 | 2017 | 170 | 1.480 |
Why?
|
| Nephrectomy | 4 | 2018 | 293 | 1.240 |
Why?
|
| Tissue Scaffolds | 2 | 2017 | 111 | 1.080 |
Why?
|
| Hepatitis C | 3 | 2021 | 170 | 1.000 |
Why?
|
| Swine | 11 | 2022 | 581 | 0.870 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2022 | 12 | 0.810 |
Why?
|
| Kidney Diseases | 3 | 2015 | 319 | 0.800 |
Why?
|
| Graft Rejection | 9 | 2021 | 1067 | 0.790 |
Why?
|
| Kidney Failure, Chronic | 3 | 2016 | 413 | 0.790 |
Why?
|
| Pancreas Transplantation | 2 | 2012 | 104 | 0.770 |
Why?
|
| Galactosyltransferases | 3 | 2017 | 40 | 0.730 |
Why?
|
| Donor Selection | 2 | 2017 | 74 | 0.680 |
Why?
|
| Immunosuppressive Agents | 3 | 2014 | 975 | 0.670 |
Why?
|
| Fluid Therapy | 2 | 2018 | 51 | 0.660 |
Why?
|
| Heat Stroke | 1 | 2018 | 9 | 0.650 |
Why?
|
| Multiple Organ Failure | 1 | 2018 | 53 | 0.630 |
Why?
|
| Waiting Lists | 2 | 2020 | 183 | 0.620 |
Why?
|
| Heterografts | 2 | 2017 | 102 | 0.620 |
Why?
|
| Animals, Genetically Modified | 5 | 2022 | 183 | 0.610 |
Why?
|
| Neuraminic Acids | 1 | 2017 | 10 | 0.600 |
Why?
|
| Postoperative Complications | 5 | 2019 | 2275 | 0.580 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2017 | 78 | 0.570 |
Why?
|
| End Stage Liver Disease | 1 | 2017 | 60 | 0.570 |
Why?
|
| Lecithin Cholesterol Acyltransferase Deficiency | 1 | 2016 | 3 | 0.570 |
Why?
|
| Bile Ducts | 1 | 2016 | 59 | 0.560 |
Why?
|
| Lung Transplantation | 2 | 2017 | 290 | 0.560 |
Why?
|
| Laparoscopy | 3 | 2018 | 771 | 0.550 |
Why?
|
| Tissue Engineering | 1 | 2017 | 185 | 0.520 |
Why?
|
| Hemofiltration | 1 | 2015 | 11 | 0.510 |
Why?
|
| Tissue and Organ Procurement | 3 | 2020 | 345 | 0.510 |
Why?
|
| Intraoperative Care | 1 | 2015 | 84 | 0.490 |
Why?
|
| Retrospective Studies | 13 | 2021 | 9003 | 0.480 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2014 | 6 | 0.470 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 173 | 0.470 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 414 | 0.460 |
Why?
|
| Male | 22 | 2020 | 42254 | 0.450 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 83 | 0.440 |
Why?
|
| Hemostasis, Surgical | 1 | 2013 | 25 | 0.440 |
Why?
|
| Immunoconjugates | 1 | 2014 | 110 | 0.430 |
Why?
|
| Humans | 30 | 2022 | 89073 | 0.430 |
Why?
|
| Membrane Cofactor Protein | 3 | 2017 | 10 | 0.420 |
Why?
|
| Gene Knockout Techniques | 3 | 2017 | 82 | 0.410 |
Why?
|
| Adult | 14 | 2020 | 26508 | 0.410 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 304 | 0.400 |
Why?
|
| Intensive Care Units | 1 | 2015 | 395 | 0.390 |
Why?
|
| Diabetic Nephropathies | 1 | 2012 | 87 | 0.390 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 311 | 0.380 |
Why?
|
| Transplantation, Homologous | 7 | 2017 | 996 | 0.380 |
Why?
|
| Thymus Gland | 5 | 2004 | 197 | 0.360 |
Why?
|
| Female | 18 | 2020 | 46014 | 0.360 |
Why?
|
| Survival Rate | 5 | 2019 | 1889 | 0.340 |
Why?
|
| Middle Aged | 14 | 2020 | 25865 | 0.340 |
Why?
|
| Animals | 15 | 2022 | 27324 | 0.310 |
Why?
|
| Rats, Wistar | 2 | 2017 | 302 | 0.280 |
Why?
|
| Extracorporeal Circulation | 2 | 2017 | 34 | 0.270 |
Why?
|
| Tissue Donors | 2 | 2020 | 490 | 0.240 |
Why?
|
| Biopsy | 2 | 2017 | 1182 | 0.220 |
Why?
|
| Risk Factors | 6 | 2020 | 5466 | 0.210 |
Why?
|
| Clodronic Acid | 1 | 2022 | 9 | 0.210 |
Why?
|
| Heme Oxygenase-1 | 1 | 2022 | 19 | 0.200 |
Why?
|
| Hematopoiesis | 1 | 2002 | 165 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 859 | 0.190 |
Why?
|
| Perfusion | 1 | 2022 | 235 | 0.190 |
Why?
|
| Hepatitis C, Chronic | 1 | 2021 | 91 | 0.180 |
Why?
|
| Renin | 1 | 2020 | 67 | 0.180 |
Why?
|
| Time Factors | 5 | 2020 | 5320 | 0.180 |
Why?
|
| Angiotensin II | 1 | 2020 | 93 | 0.180 |
Why?
|
| Vasoconstrictor Agents | 1 | 2020 | 56 | 0.180 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 81 | 0.170 |
Why?
|
| Reoperation | 3 | 2012 | 598 | 0.170 |
Why?
|
| Papio | 2 | 2014 | 82 | 0.170 |
Why?
|
| Shock, Septic | 1 | 2020 | 104 | 0.170 |
Why?
|
| CD55 Antigens | 2 | 2017 | 21 | 0.160 |
Why?
|
| T-Lymphocytes | 2 | 2003 | 1223 | 0.160 |
Why?
|
| Liver Failure, Acute | 1 | 2018 | 39 | 0.160 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 167 | 0.160 |
Why?
|
| Kupffer Cells | 1 | 2017 | 13 | 0.150 |
Why?
|
| Liver Diseases | 1 | 2020 | 242 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 280 | 0.150 |
Why?
|
| Hernia, Umbilical | 1 | 2017 | 17 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 3657 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2019 | 162 | 0.150 |
Why?
|
| Craniocerebral Trauma | 1 | 2017 | 56 | 0.150 |
Why?
|
| Cell Tracking | 1 | 2016 | 14 | 0.140 |
Why?
|
| Hepatocytes | 1 | 2017 | 119 | 0.140 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 48 | 0.140 |
Why?
|
| Cell Compartmentation | 1 | 2016 | 69 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2017 | 299 | 0.140 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 68 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2019 | 386 | 0.140 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 181 | 0.140 |
Why?
|
| Social Support | 1 | 2018 | 208 | 0.140 |
Why?
|
| Albumins | 1 | 2016 | 129 | 0.140 |
Why?
|
| Immune Tolerance | 3 | 2004 | 338 | 0.140 |
Why?
|
| Inflammation | 1 | 2022 | 971 | 0.130 |
Why?
|
| Heart Arrest | 1 | 2019 | 279 | 0.130 |
Why?
|
| Sildenafil Citrate | 1 | 2015 | 23 | 0.130 |
Why?
|
| Maryland | 1 | 2015 | 42 | 0.130 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 10 | 0.130 |
Why?
|
| Violence | 1 | 2017 | 153 | 0.130 |
Why?
|
| Cell Lineage | 1 | 2016 | 291 | 0.130 |
Why?
|
| Risk Assessment | 4 | 2020 | 2291 | 0.130 |
Why?
|
| Animals, Newborn | 1 | 2016 | 524 | 0.130 |
Why?
|
| Robotics | 1 | 2018 | 269 | 0.130 |
Why?
|
| Aged | 3 | 2017 | 19078 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 1796 | 0.120 |
Why?
|
| Endothelial Cells | 1 | 2017 | 459 | 0.120 |
Why?
|
| Comorbidity | 1 | 2018 | 948 | 0.120 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2016 | 141 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 2 | 2015 | 275 | 0.120 |
Why?
|
| von Willebrand Factor | 1 | 2014 | 37 | 0.120 |
Why?
|
| Abatacept | 1 | 2014 | 85 | 0.120 |
Why?
|
| Endoscopy | 1 | 2017 | 348 | 0.110 |
Why?
|
| Organ Transplantation | 1 | 2017 | 275 | 0.110 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 254 | 0.110 |
Why?
|
| Ligation | 1 | 2013 | 51 | 0.110 |
Why?
|
| Length of Stay | 2 | 2016 | 732 | 0.110 |
Why?
|
| Patient Selection | 1 | 2017 | 682 | 0.110 |
Why?
|
| Kidney | 4 | 2015 | 1145 | 0.110 |
Why?
|
| Histocompatibility | 3 | 2017 | 66 | 0.110 |
Why?
|
| Swine, Miniature | 5 | 2003 | 50 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 988 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2880 | 0.100 |
Why?
|
| Heart Transplantation | 1 | 2017 | 717 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1149 | 0.100 |
Why?
|
| C-Peptide | 1 | 2012 | 179 | 0.100 |
Why?
|
| Wisconsin | 1 | 2011 | 41 | 0.100 |
Why?
|
| Rats | 1 | 2017 | 4041 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2020 | 8203 | 0.090 |
Why?
|
| DNA | 1 | 2016 | 1307 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1650 | 0.090 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2002 | 241 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2752 | 0.090 |
Why?
|
| Islets of Langerhans | 2 | 2002 | 548 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 848 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2011 | 948 | 0.080 |
Why?
|
| Biomarkers | 1 | 2014 | 1755 | 0.070 |
Why?
|
| Disease Progression | 1 | 2011 | 1488 | 0.070 |
Why?
|
| Incidence | 1 | 2011 | 1592 | 0.070 |
Why?
|
| Young Adult | 1 | 2018 | 6289 | 0.070 |
Why?
|
| Pancreatectomy | 2 | 2002 | 158 | 0.060 |
Why?
|
| Prognosis | 1 | 2011 | 3773 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2011 | 4273 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1837 | 0.050 |
Why?
|
| Transplantation Tolerance | 1 | 2003 | 138 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2021 | 129 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 112 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2001 | 369 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2002 | 836 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2021 | 475 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 559 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2018 | 251 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 850 | 0.030 |
Why?
|
| Wound Healing | 1 | 2018 | 359 | 0.030 |
Why?
|
| Pain, Postoperative | 1 | 2018 | 251 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 216 | 0.030 |
Why?
|
| Operative Time | 1 | 2016 | 142 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 115 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 240 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1715 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2016 | 166 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2015 | 119 | 0.030 |
Why?
|
| Transplantation, Heterotopic | 2 | 2003 | 46 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 461 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 351 | 0.030 |
Why?
|
| Insulin | 2 | 2002 | 1146 | 0.020 |
Why?
|
| United States | 1 | 2020 | 6957 | 0.020 |
Why?
|
| Immunotoxins | 1 | 2003 | 14 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2003 | 73 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2003 | 84 | 0.010 |
Why?
|
| Surgically-Created Structures | 1 | 2002 | 5 | 0.010 |
Why?
|
| Omentum | 1 | 2003 | 73 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2003 | 237 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 293 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2002 | 301 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2002 | 172 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 353 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2001 | 137 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2001 | 165 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2001 | 201 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 894 | 0.010 |
Why?
|
| Haplotypes | 1 | 2001 | 637 | 0.010 |
Why?
|